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Abstract This report concerns two new mutations in the 
sterol 27-hydroxylase gene in two patients with cerebro­
tendinous xanthomatosis (CTX). In a Surinam-Creole pa­
tient (patient A), a G deletion on position cDNA 546/547 
in exon 3 led to a frameshift and the introduction of a pre­
mature termination codon. In a Dutch patient (patient B), 
a C->T transition at position 496 in exon 3 also led to a 
premature termination codon. Patient A was homozygous 
for the mutation, whereas patient B was compound het­
erozygous, a C—>T transition also being found in exon 6 at 
position 1204. The two new mutations were confirmed by 
restriction analysis with the restriction enzymes Fold and 
Mae I, respectively.
Introduction
Cerebrotendinous xanthomatosis (CTX; McKusick 213700), 
first described by van Bogaert et al. in 1937, is a rare, au­
tosomal recessive, lipid-storage disease characterised by 
abnormal bile acid synthesis caused by a deficiency of the 
mitochondrial enzyme sterol 27-hydroxylase (CYP 27; 
Oftebro et al. 1981). This deficiency leads to reduced syn­
thesis of cholic acid and almost no ehenodeoxycholic acid 
(CDCA) is produced. The absence of the negative feed­
back mechanism of CDCA on 7a-hydroxylase, the rate- 
limiting enzyme in bile acid synthesis, leads to an exces­
sive production of cholestanol, which accumulates in 
many tissues (Bjorkhem et al. 1995). In CTX, bile alco­
hols are produced via 24- and 25-hydroxylation of 5(}- 
cholestane-3cx,7oc,12a-triol. The biochemical diagnosis is
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made by determination of bile alcohols in urine and by the 
determination of the serum cholestanol/cholesterol ratio
(CCR; Wolthers et al. 1983).
The climcal characteristics of CTX are premature bi­
lateral cataract, formation of tendon xanthomas and neu­
rological and neuropsychiatric abnormalities, i.e. pyrami­
dal and cerebellar signs, peripheral neuropathy and de­
mentia (Bjorkhem and Boherg 1995). Although the dis­
ease manifests itself in childhood in many patients, the di­
agnosis of CTX is rarely made before the age of 20. Since 
early treatment with chenodeoxycholic acid is able to sta­
bilise or even reverse the disease in its initial stages 
(Berginer et al. 1984, 1994), CTX should be considered as 
a diagnosis as early as possible.
Andersson et al. (1989) have described the cDNA that 
encodes rabbit mitochondrial CYP 27, a member of the 
mitochondrial cytochrome P450 enzyme family. The cDNA 
for the human CYP 27 has been cloned (Cali et al. 1991) 
and its gene localised on chromosome 2 (q33-qter) by 
Cali and Russell (1991). The structure of the CYP 27 gene 
has been established bv Leitersdorf et al. (1993).
*  ^
To date, 14 different mutations have been described in 
the CYP 27 gene in CTX patients. This report describes 




This 35-year-old woman presented with Achilles tendon xanthomas 
at the age of 17. She subsequently developed visual impairment 
caused by bilateral cataract. Her cognitive function gradually dete­
riorated; psychiatric disturbances and epilepsy developed. The di­
agnosis of CTX was made at the age of 33 years by determination 
of a high concentration of bile alcohols (5(3-cholestane-3a,7a, 
12a,23,25 pentol and 5|3-eholestane-3oc,7a,12<x24,25 pentol) in 
her urine. She had four healthy brothers.
Patient B
This 56-year-old woman was diagnosed as having CTX, after 16 
years of progressive spastic tetraparesis and severe mental deterio-
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Discussion
To date, 14 mutations have been reported in the CYP 27 
gene of CTX patients; 8 missense mutations (Kim et al. 
1994; Cali et al. 1991; Reshef et a l  1994; Nakashima et 
al. 1994; Watts et al. 1996; Okuyama et al. 1996), 2 dele­
tions and one insertion leading to a frameshift (Leitersdorf 
et al. 1993, 1994; Segev et al. 1995), one splice acceptor 
site mutation (Leitersdorf et al. 1993), one premature ter­
mination codon (Meiner et al. 1994) and one partial dele­
tion of the gene (Garuti et al. 1996). Of these 14 muta­
tions, one is in exon 1, three in exon 2, one in exon 4 and 
one in intron 4, two in exon 5, one in exon 6, one in exon 
7 and three in exon 8. The partial deletion of the gene 
spans the region from intron 6 to the 3' flanking region 
eliminating exons 7-9  (Garuti et al. 1996).
In this study, two clinically-established CTX cases 
were investigated for mutations in the CYP 27 gene. DNA 
from both patients was PCR-amplified with primers tar­
geted at exons 1-9 of this gene. SSCP analysis of exon 3 
of patient A and of exons 3 and 6 of patient B showed an 
abnormal migration pattern. Direct sequencing of these 
exons demonstrated three mutations.
In exon 3 of patient A, there was a (cDNA) 546/547 G 
deletion leading to a frameshift with the introduction of 5 
different amino acids (Met-Leu-Ser-Met-Arg) and a pre­
mature termination codon in exon 3. The patient was ho­
mozygous for this mutation.
In exon 3 of patient B, a 496 C—>T transition changed 
codon 126 into a premature termination codon. In this pa­
tient, a second mutation, viz. a 1204 C ^ T  transition, was 
found in exon 6. This missense mutation has been de­
scribed by Cali et al. (1991). Patient B is therefore proba­
bly a compound heterozygote for these mutations.
The conserved parts of the gene are located in the re­
gions of exon 6-8. The expressed enzymes in both muta­
tions therefore presumably lack a stretch of amino acids 
essential for the function of the enzyme.
A cknow ledgem ents  The authors would like to thank J. J. P. 
Kastelein, Academic Medical Centre, Amsterdam, and J. W. B. 
Moll, University Hospital Rotterdam, for referring the patients.
References
Andersson S, Davis D, Dahlback H, Jornvall H, Russell DW 
(1989) Cloning, structure and expression of the mitochondrial 
cytochrome P-450 sterol 26-hydroxylase, a bile acid biosyn­
thetic enzyme. J Biol Chem 264:8222-8229 
Berginer VM, Salen G, Shefer S (1984) Long-term treatment of 
cerebrotendinous xanthomatosis with chenodeoxycholic acid.
N Engl J Med 311:1649-1652 
Berginer VM, Berginer J, Korczyn AD, Tadmor R (1994) Mag­
netic resonance imaging in cerebrotendinous xanthomatosis: a 
prospective clinical and neuroradiological study. J Neurol Sei
122:102-108
Björkhem I, Boberg KM (1995) Inborn errors in bile acid biosyn­
thesis and storage of sterols other than cholesterol, in: Seriver 
C (ed) The metabolic and molecular bases of inherited dis­
ease,7th edn. McGraw-Hill, New York, pp 2273-2299 
Bogaert L van, Scherer H, Epstein E (1937) Une forme cérébrale 
de la cholestérinose généralisée. Masson et Cie, Paris 
Cali JJ, Russell DW (1991) Characterization of human sterol 27- 
hydroxylase. J Biol Chem 266:7774-7778 
Cali JJ, Hsieh CL, Francke U, Russell DW ( 1991) Mutations in the 
bile acid biosynthetic enzyme sterol 27-hydroxylase underlie 
cerebrotendinous xanthomatosis. J Biol Chem 266:7779-77X3 
Garuti R, Lelli N, Barozzini M, Dotli MT, Federico A, Bertolini S, 
Calandra S (1996) Partial deletion of the gene encoding sterol 
27-hydroxylase in a subject with cerebrotendinous xanthomato­
sis. J Lipid Res 37:662-672 
Kim KS, Kubota S, Kuriyama M, Fujiyama J, Björkhem I, Eggert- 
sen G, Seyama Y (1994) Identification of new mutations in 
sterol 27-hydroxylase gene in Japanese patients with cerebro­
tendinous xanthomatosis (CTX). J Lipid Res 35:1031-1039 
Leitersdorf E, Reshef A, Meiner V, Levitzki R, Schwartz SP, Dann 
EJ, Berkman N, Cali JJ, Klapholz L, Berginer VM (1993) 
Frameshift and splice-junction mutations in the sterol 27-hy­
droxylase gene cause cerebrotendinous xanthomatosis in Jews 
of Moroccan origin. J Clin Invest 91:2488-2496 
Leitersdorf E, Safadi R, Meiner V, Reshef A, Björkhem I, Fried- 
lander Y, Morkos S, Berginer VM (1994) Cerebrotendinous 
xanthomatosis in the Israeli Druze: molecular genetics and phe­
notypic characteristics. Am J Hum Genet 55:907-915 
Meiner V, Marais DA, Reshef A, Björkhem I, Leitersdorf E (1994) 
Premature termination codon at the sterol 27-hydroxylase gene 
causes cerebrotendinous xanthomatosis in an Afrikaner family. 
Hum Mol Genet 3:193-194 
Nakashima N, Sakai Y, Sakai H, Yanase T, Haji M, Umeda F, 
Koga S, Hoshita T, Nawata H (1994) A point mutation in the 
bile acid biosynthetic enzyme sterol 27-hydroxylase in a family 
with cerebrotendinous xanthomatosis. J Lipid Res 35:663-668 
Oftebro H, Björkhem I, Stornier FC, Pedersen JI (1981) Cerebro­
tendinous xanthomatosis: defective liver mitochondrial hy­
droxylation of chenodeoxycholic acid precursors. J Lipid Res
22:632-640
Okuyama E, Tomita S, Takeuchi H, Ichikawa Y < 1996) A novel 
mutation in the cytochrome P45027 (CYP27) gene caused cere­
brotendinous xanthomatosis in a Japanese family. J Lipid Res
37:631-639
Reshef A, Meiner V, Berginer VM, Leitersdorf E (1994) Molecu­
lar genetics of cerebrotendinous xanthomatosis in Jews of 
north African origin. J Lipid Res 35:478-483 
Segev H, Reshef A, Clavey V, Delbart C, Routier G, Leitersdorf E 
(1995) Premature termination codon at the sterol 27-hydroxy­
lase gene causes cerebrotendinous xanthomatosis in a French 
family. Hum Genet 95:238-240 
Watts G, Mitchell W, Bending J, Reshef A, Leitersdorf E (1996) 
Cerebrotendinous xanthomatosis: a family study of sterol 27- 
hydroxylase mutations and pharmacotherapy. Q J Med 89:55- 
63
Wolthers BG, Volmer M, Molen J van der, Koopman BJ, Jager AE 
de, Waterreus RJ (1983) Diagnosis of cerebrotendinous xan­
thomatosis (CTX ) and effect of chenodeoxycholic acid therapy 
by analysis of urine using capillary gas chromatography. Clin
Chim Acta 131:53-65 
Wolthers BG, Walrecht HT, Molen JC van der, Nagel GT, Van 
Doormaal JJ, Wijnandts PN (1991) Use of determinations of 7- 
lathosterol (5-alpha-cholest-7-en-3-beta-ol) and other choles­
terol precursors in serum in the study and treatment ot distur­
bances of sterol metabolism, particularly cerebrotendinous 
xanthomatosis. J Lipid Res 32:603-612
